AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Core Points - AIM ImmunoTech Inc. has received approval from NYSE American for its plan to regain compliance with minimum stockholders' equity requirements, with a deadline set for June 11, 2026 [1][2] - The company is focused on advancing its oncology and antiviral pipelines while executing its compliance strategy [2] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad-spectrum activity in clinical trials [2]